Market Closed -
Nasdaq
04:00:00 2024-06-05 pm EDT
|
5-day change
|
1st Jan Change
|
0.9475
USD
|
-2.17%
|
|
+5.11%
|
-31.34%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
5,426
|
4,855
|
2,872
|
700.4
|
573.7
|
186.7
|
186.7
|
-
|
Enterprise Value (EV)
1 |
4,194
|
3,749
|
1,721
|
400.9
|
393.4
|
-53.93
|
80.67
|
122.8
|
P/E ratio
|
-9.29
x
|
-6.13
x
|
-4.35
x
|
-0.84
x
|
-2.04
x
|
-0.57
x
|
-0.59
x
|
-1.18
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
99.4
x
|
109
x
|
11.5
x
|
191
x
|
160
x
|
4.99
x
|
1.33
x
|
0.71
x
|
EV / Revenue
|
76.8
x
|
83.9
x
|
6.86
x
|
109
x
|
109
x
|
-1.44
x
|
0.58
x
|
0.47
x
|
EV / EBITDA
|
-7.56
x
|
-4.7
x
|
-2.85
x
|
-0.7
x
|
-1.04
x
|
0.2
x
|
-0.35
x
|
-0.88
x
|
EV / FCF
|
-8.94
x
|
-5.9
x
|
-3.45
x
|
-0.62
x
|
-
|
0.16
x
|
-0.25
x
|
-0.52
x
|
FCF Yield
|
-11.2%
|
-16.9%
|
-29%
|
-162%
|
-
|
606%
|
-400%
|
-191%
|
Price to Book
|
2.88
x
|
3.78
x
|
2.12
x
|
1.9
x
|
2.92
x
|
0.46
x
|
1.29
x
|
1.51
x
|
Nbr of stocks (in thousands)
|
54,694
|
55,331
|
66,373
|
70,107
|
82,910
|
192,742
|
192,742
|
-
|
Reference price
2 |
99.20
|
87.75
|
43.27
|
9.990
|
6.920
|
0.9475
|
0.9475
|
0.9475
|
Announcement Date
|
2/21/19
|
2/18/20
|
2/23/21
|
3/4/22
|
3/29/23
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
54.58
|
44.67
|
250.7
|
3.662
|
3.597
|
37.41
|
140.1
|
262
|
EBITDA
1 |
-554.9
|
-797.4
|
-603.7
|
-571.3
|
-379.2
|
-266.4
|
-230.2
|
-139.5
|
EBIT
1 |
-572
|
-814.8
|
-623
|
-590.9
|
-384.2
|
-276.3
|
-264.2
|
-191
|
Operating Margin
|
-1,048.06%
|
-1,823.94%
|
-248.49%
|
-16,136.29%
|
-10,679.79%
|
-738.59%
|
-188.56%
|
-72.89%
|
Earnings before Tax (EBT)
1 |
-555.4
|
-790.2
|
-618
|
-562.4
|
-266.5
|
-198.8
|
-254.6
|
-183.3
|
Net income
1 |
-555.6
|
-789.6
|
-618.7
|
-819.4
|
-266.6
|
-199.1
|
-243.8
|
-174.2
|
Net margin
|
-1,018.02%
|
-1,767.49%
|
-246.75%
|
-22,375.15%
|
-7,411.12%
|
-532.3%
|
-174%
|
-66.51%
|
EPS
2 |
-10.68
|
-14.31
|
-9.950
|
-11.89
|
-3.390
|
-1.664
|
-1.612
|
-0.8052
|
Free Cash Flow
1 |
-469.2
|
-635.4
|
-499.3
|
-650.1
|
-
|
-327
|
-323
|
-235
|
FCF margin
|
-859.6%
|
-1,422.33%
|
-199.15%
|
-17,753.74%
|
-
|
-874.06%
|
-230.53%
|
-89.71%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/21/19
|
2/18/20
|
2/23/21
|
3/4/22
|
3/29/23
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
7.472
|
22.68
|
1.606
|
1.945
|
1.519
|
0.071
|
0.062
|
2.381
|
6.89
|
12.39
|
14.49
|
17.11
|
23.06
|
33.26
|
50.55
|
EBITDA
1 |
-234.8
|
-190.8
|
-133.4
|
-119.3
|
-99.42
|
-85.09
|
-75.31
|
-83.41
|
-84.33
|
-83.66
|
-102.3
|
-
|
-
|
-
|
-
|
EBIT
1 |
-240.8
|
-196.8
|
-135.7
|
-120.3
|
-100.8
|
-86.48
|
-76.56
|
-84.49
|
-85.3
|
-84.73
|
-87.45
|
-76.62
|
-74.51
|
-64.71
|
-54.8
|
Operating Margin
|
-3,223.21%
|
-867.75%
|
-8,447.51%
|
-6,187.46%
|
-6,633.38%
|
-121,802.82%
|
-123,491.94%
|
-3,548.64%
|
-1,237.98%
|
-683.74%
|
-603.34%
|
-447.84%
|
-323.07%
|
-194.57%
|
-108.4%
|
Earnings before Tax (EBT)
1 |
-241.5
|
-216.9
|
-132.2
|
-122.2
|
-100.1
|
-76.51
|
32.34
|
21.24
|
-72.99
|
-71.73
|
-79.2
|
-75
|
-75.31
|
-60.26
|
-52.68
|
Net income
1 |
-241.7
|
-216.8
|
-155.1
|
-122.2
|
-100.1
|
-76.52
|
32.23
|
21.24
|
-72.91
|
-71.73
|
-83.7
|
-71.05
|
-72.36
|
-59.22
|
-49.11
|
Net margin
|
-3,234.77%
|
-956.11%
|
-9,654.55%
|
-6,280.31%
|
-6,592.36%
|
-107,774.65%
|
51,987.1%
|
892.06%
|
-1,058.17%
|
-578.85%
|
-577.49%
|
-415.29%
|
-313.71%
|
-178.06%
|
-97.14%
|
EPS
2 |
-3.580
|
-3.160
|
-2.140
|
-1.660
|
-1.360
|
-0.9400
|
0.3800
|
0.2100
|
-0.6700
|
-0.6600
|
-0.6281
|
-0.4257
|
-0.4171
|
-0.3643
|
-0.3067
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/9/21
|
11/5/21
|
3/4/22
|
5/9/22
|
8/4/22
|
11/7/22
|
3/29/23
|
5/9/23
|
8/8/23
|
11/7/23
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
1,232
|
1,106
|
1,151
|
300
|
180
|
241
|
106
|
63.9
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-469
|
-635
|
-499
|
-650
|
-
|
-327
|
-323
|
-235
|
ROE (net income / shareholders' equity)
|
-31.7%
|
-49.8%
|
-46.9%
|
-94.8%
|
-93.4%
|
-105%
|
-122%
|
-113%
|
ROA (Net income/ Total Assets)
|
-26.8%
|
-39.8%
|
-35.3%
|
-69%
|
-
|
-40.5%
|
-80.2%
|
-88.1%
|
Assets
1 |
2,072
|
1,985
|
1,754
|
1,188
|
-
|
492.3
|
304
|
197.8
|
Book Value Per Share
2 |
34.40
|
23.20
|
20.40
|
5.260
|
2.370
|
2.040
|
0.7300
|
0.6300
|
Cash Flow per Share
2 |
-7.950
|
-10.20
|
-7.560
|
-9.220
|
-4.490
|
-1.720
|
-1.130
|
-0.7400
|
Capex
1 |
55.7
|
71
|
29
|
14.5
|
8.21
|
6.99
|
7.54
|
8.09
|
Capex / Sales
|
102.12%
|
158.99%
|
11.56%
|
396.04%
|
228.19%
|
18.68%
|
5.38%
|
3.09%
|
Announcement Date
|
2/21/19
|
2/18/20
|
2/23/21
|
3/4/22
|
3/29/23
|
-
|
-
|
-
|
Last Close Price
0.9475
USD Average target price
3.795
USD Spread / Average Target +300.48% Consensus |
1st Jan change
|
Capi.
|
---|
| -31.34% | 187M | | +18.72% | 123B | | +14.53% | 107B | | -2.88% | 24.01B | | +2.18% | 22.59B | | -10.09% | 18.16B | | -41.04% | 16.84B | | -11.83% | 16.23B | | +1.46% | 13.43B | | +24.22% | 11.32B |
Bio Therapeutic Drugs
|